

**Notice Declaring Intention to be Qualified under National Instrument 44-101**  
***Short Form Prospectus Distributions* (“NI 44-101”)**

July 2, 2014

To: Ontario Securities Commission  
British Columbia Securities Commission  
Alberta Securities Commission

Revive Therapeutics Ltd. (the “**Issuer**”) intends to be qualified to file a short form prospectus under NI 44-101. The Issuer acknowledges that it must satisfy all applicable qualification criteria prior to filing a preliminary short form prospectus. This notice does not evidence the Issuer’s intent to file a short form prospectus, to enter into any particular financing or transaction or to become a reporting issuer in any jurisdiction. This notice will remain in effect until withdrawn by the Issuer.

**REVIVE THERAPEUTICS LTD.**

“Fabio Chianelli”

Fabio Chianelli  
Chief Executive Officer